138 related articles for article (PubMed ID: 32038766)
1. IncobotulinumtoxinA for the Treatment of Glabellar Frown Lines: A Prospective, Multicenter, Single-arm Study in Taiwan.
Chao YY; Tseng FW; Yang YL; Chen YH; Hsu NJ; Chang LY
J Clin Aesthet Dermatol; 2019 Dec; 12(12):E53-E57. PubMed ID: 32038766
[No Abstract] [Full Text] [Related]
2. Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study.
Prager W; Bee EK; Havermann I; Zschocke I
Clin Interv Aging; 2013; 8():449-56. PubMed ID: 23650444
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines.
Lim JTE; Loh DK; Soh K; Sunga O
Singapore Med J; 2017 Oct; 58(10):606-609. PubMed ID: 27357317
[TBL] [Abstract][Full Text] [Related]
4. A Phase III Study of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines.
Imhof M; Kühne U
J Clin Aesthet Dermatol; 2011 Oct; 4(10):28-34. PubMed ID: 22010053
[TBL] [Abstract][Full Text] [Related]
5. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.
Carruthers A; Carruthers J; Coleman WP; Donofrio L; Flynn T; Gold M; Heinz M; Harrington L; Jones D; McDaniel D; Rohrer T; Schlöbe A; Solish N; Weiss RA
Dermatol Surg; 2013 Apr; 39(4):551-8. PubMed ID: 23379292
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Tolerability of IncobotulinumtoxinA for Treating Glabellar Frown Lines in Korean Adults: A Postmarketing Observational Study.
Park JY; Sung NK; Pitt JM
Dermatol Surg; 2017 Dec; 43 Suppl 3():S304-S311. PubMed ID: 28961638
[TBL] [Abstract][Full Text] [Related]
7. IncobotulinumtoxinA for Glabellar Frown Lines in Chinese Subjects: A Randomized, Double-blind, Active-Controlled Phase-3 Study.
Wu Y; Roll S; Klein G; Geister TL; Makara MA; Li B
Plast Reconstr Surg Glob Open; 2023 May; 11(5):e4956. PubMed ID: 37250827
[TBL] [Abstract][Full Text] [Related]
8. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
Prager W; Rappl T
J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Lateral Periorbital Lines with Different Dilutions of IncobotulinumtoxinA.
Muti GF; Basso M
J Clin Aesthet Dermatol; 2017 Sep; 10(9):27-29. PubMed ID: 29344324
[No Abstract] [Full Text] [Related]
10. IncobotulinumtoxinA use in aesthetic indications in daily practice: a European multicenter, noninterventional, retrospective study.
Pavicic T; Prager W; Klöppel M; Ravichandran S; Galatoire O
Clin Cosmet Investig Dermatol; 2015; 8():135-42. PubMed ID: 25834463
[TBL] [Abstract][Full Text] [Related]
11. Long-term results for incobotulinumtoxinA in the treatment of glabellar frown lines.
Rzany B; Flynn TC; Schlöbe A; Heinz M; Harrington L
Dermatol Surg; 2013 Jan; 39(1 Pt 1):95-103. PubMed ID: 23190342
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of incobotulinumtoxinA for treatment of glabellar frown lines: a post hoc pooled analysis of 2 randomized, placebo-controlled, phase 3 trials.
Jones D; Carruthers J; Narins RS; Coleman WP; Harrington L; Brandt FS; Cohen JL
Dermatol Surg; 2014 Jul; 40(7):776-85. PubMed ID: 25111351
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results From a Randomized, Double-Blind, Placebo-Controlled, Phase III Study.
Kerscher M; Rzany B; Prager W; Turnbull C; Trevidic P; Inglefield C
Dermatol Surg; 2015 Oct; 41(10):1149-57. PubMed ID: 26359996
[TBL] [Abstract][Full Text] [Related]
14. IncobotulinumtoxinA Is an Effective and Well-Tolerated Treatment for Upper Facial Lines: Results From an Open-Label Extension Period of a Phase III Study.
Trevidic P; Connolly SA; Biwer B; Ellers-Lenz B; Harrington LS; Kestemont P; Noah EM; Sattler G; Weissenberger P; Kerscher M
Dermatol Surg; 2017 Dec; 43 Suppl 3():S285-S292. PubMed ID: 33065954
[TBL] [Abstract][Full Text] [Related]
15. The South American Glabellar Experience Study (SAGE): a multicenter retrospective analysis of real-world treatment patterns following the introduction of incobotulinumtoxinA in Argentina.
Banegas RA; Farache F; Rancati A; Chain M; Gallagher CJ; Chapman MA; Caulkins CA
Aesthet Surg J; 2013 Sep; 33(7):1039-45. PubMed ID: 23990584
[TBL] [Abstract][Full Text] [Related]
16. A Randomized, Double-Blind Trial to Investigate the Equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for Glabellar Frown Lines.
Kane MA; Gold MH; Coleman WP; Jones DH; Tanghetti EA; Alster TS; Rohrer TE; Burgess CM; Shamban AT; Finn E
Dermatol Surg; 2015 Nov; 41(11):1310-9. PubMed ID: 26509943
[TBL] [Abstract][Full Text] [Related]
17. Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study.
Rappl T; Parvizi D; Friedl H; Wiedner M; May S; Kranzelbinder B; Wurzer P; Hellbom B
Clin Cosmet Investig Dermatol; 2013; 6():211-9. PubMed ID: 24098087
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint.
Hanke CW; Narins RS; Brandt F; Cohen JL; Donofrio LM; Downie J; Heinz M; Harrington L; McDaniel DH; Nestor M; Schlessinger J; Schlöbe A; Taub A; Weiss RA
Dermatol Surg; 2013 Jun; 39(6):891-9. PubMed ID: 23506308
[TBL] [Abstract][Full Text] [Related]
19. Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines.
Prager W
Clin Pharmacol; 2013; 5():39-52. PubMed ID: 23516136
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of IncobotulinumtoxinA for the Treatment of Glabellar Frown Lines in Male Subjects: Post-Hoc Analyses From Randomized, Double-Blind Pivotal Studies.
Jones DH; Kerscher M; Geister T; Hast MA; Weissenberger P
Dermatol Surg; 2017 Nov; 43 Suppl 2():S235-S241. PubMed ID: 29064991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
